| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
Papers In Press, published online ahead of print December 1, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intrinsic Bioprobes Inc., Tempe, AR 85281
Corresponding Author: rnelson{at}intrinsicbio.com
Novel mass spectrometric immunoassays for the isolation and structural characterization of plasma apolipoproteins A-I, A-II and E have been developed. The assays combine selective isolation of apolipoprotein species via affinity capture with mass-specific detection using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). In application, plasma (from 50
Revised on November 4, 2002
Accepted on November 26, 2002
Novel Mass Spectrometric Immunoassays for the Rapid Structural Characterization of Plasma Apolipoproteins
L of whole blood drawn from individuals using finger lancet) was addressed with affinity pipette tips derivatized with antibodies toward the specific apolipoprotein. The time required for each assay was ~ 15 minutes, less if assays on multiple individuals were performed in parallel. In a brief study of five individuals, several as yet un-reported apoA-II variants were identified and observed consistently in all individuals. Additionally, the apoE phenotype of E3/E3 was observed in three of the individuals, and E2/E3 and E3/E4 observed in the remaining two individuals, the latter of which suffers from Alzheimer’s disease. Overall, the mass spectrometric immunoassay approach offers a rapid, sensitive and highly accurate means of profiling apolipoproteins from small volumes of plasma.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  E. E. Niederkofler, U. A. Kiernan, J. O'Rear, S. Menon, S. Saghir, A. A. Protter, R. W. Nelson, and U. Schellenberger Detection of Endogenous B-Type Natriuretic Peptide at Very Low Concentrations in Patients With Heart Failure Circ Heart Fail, November 1, 2008; 1(4): 258 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nedelkov, D. A. Phillips, K. A. Tubbs, and R. W. Nelson Investigation of Human Protein Variants and Their Frequency in the General Population Mol. Cell. Proteomics, July 1, 2007; 6(7): 1183 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nedelkov, U. A. Kiernan, E. E. Niederkofler, K. A. Tubbs, and R. W. Nelson Population Proteomics: The Concept, Attributes, and Potential for Cancer Biomarker Research Mol. Cell. Proteomics, October 1, 2006; 5(10): 1811 - 1818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. de Bont, M. L. den Boer, R. E. Reddingius, J. Jansen, M. Passier, R. H.N. van Schaik, J. M. Kros, P. A.E. Sillevis Smitt, T. H. Luider, and R. Pieters Identification of Apolipoprotein A-II in Cerebrospinal Fluid of Pediatric Brain Tumor Patients by Protein Expression Profiling Clin. Chem., August 1, 2006; 52(8): 1501 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nedelkov, U. A. Kiernan, E. E. Niederkofler, K. A. Tubbs, and R. W. Nelson Investigating diversity in human plasma proteins PNAS, August 2, 2005; 102(31): 10852 - 10857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Malik, M. D. Ward, S. K. Gupta, M. W. Trosset, W. E. Grizzle, B.-L. Adam, J. I. Diaz, and O. J. Semmes Serum Levels of an Isoform of Apolipoprotein A-II as a Potential Marker for Prostate Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1073 - 1085. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
